EPICS’s partner for in silico modeling, Cresset, released a seminal article in Journal of Medicinal Chemistry, about methods available for ranking Ligand-Protein interactions. Our proof-of-concept METTL3 inhibitor, EP652, was used to highlight how Electrostatic Complementarity (EC) can be successfully used in design.
